![](/images/award_icon.png)
Hybrid repellant-antimicrobial gemini coatings for prevention of catheter-associated bloodstream infectionsAward last edited on: 2/9/2024
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$273,485Award Phase
1Solicitation Topic Code
855Principal Investigator
Kollbe AhnCompany Information
Phase I
Contract Number: 1R43AI177051-01Start Date: 3/22/2023 Completed: 2/29/2024
Phase I year
2023Phase I Amount
$273,485Public Health Relevance Statement:
Project Narrative/Public Health Statement In the United States each year more than 400,000 Americans undergoing hemodialysis therapy receive placement of a central venous catheter (CVC, or central line), and more than 20% of these suffer from a central line-associated bloodstream infection (CLABSI) with mortality rates estimated at 14-40% as a result. CLABSI pathology is exacerbated by the formation of highly adherent biofilms to the CVC surface. In this SBIR ACatechol proposes to develop a hybrid CVC, providing both antimicrobial efficacy and biofilm repellency simultaneously, to prevent the root cause (i.e., biofilm formation) that current CVCs fail to adequately address.
Project Terms:
Anti-Infective Drugs; Anti-Infectives; Anti-infective Preparation; AntiInfective Drugs; AntiInfectives; Antiinfective Agents; communicable disease control agent; Anti-Infective Agents; Antibiotic Agents; Antibiotic Drugs; Miscellaneous Antibiotic; Antibiotics; Biological Assay; Assay; Bioassay; Biologic Assays; Biotechnology; Biotech; Blood; Blood Reticuloendothelial System; Certification; Complement Activation; complement pathway regulation; Equilibrium; balance; balance function; Goals; Cyclic GMP; Guanosine Cyclic Monophosphate; cGMP; Healthcare Systems; Health Care Systems; Hemodialysis; Hemodialyses; Hemolysis; erythrolysis; Heparin; Heparinic Acid; Hybrids; Immobilization; orthopedic freezing; In Vitro; Infection; Inflammation; Kidney Diseases; Nephropathy; Renal Disease; kidney disorder; renal disorder; Marketing; Medical Device; mortality; Pain; Painful; Pathology; Patients; Play; Polymers; polymer; polymeric; Production; Public Health; Risk; Technology; Translations; translation; United States; Urinary tract; Microbial Biofilms; biofilm; Health Costs; Healthcare Costs; Health Care Costs; Catheters; Resistance to antibiotics; Resistant to antibiotics; antibiotic drug resistance; antibiotic resistant; Antibiotic Resistance; Surface; Specified; Specific qualifier value; Phase; Ensure; Susceptibility; Predisposition; Licensing; Relative Risks; tool; Venous; Knowledge; Life; Mechanics; mechanic; mechanical; Frequencies; Biocide; microorganism; American; biomaterial compatibility; biocompatibility; experience; hydrophilicity; synergism; microbial; Toxic effect; Toxicities; novel; technological innovation; Prevention; Property; surface coating; Manufacturer; preventing; prevent; Coagulation Process; Clotting; Coagulation; Address; Antimicrobial Resistance; Antimicrobial resistant; Resistance to antimicrobial; anti-microbial resistance; anti-microbial resistant; resistance to anti-microbial; resistant to anti-microbial; resistant to antimicrobial; Adherence; Data; Proliferating; in vivo; research clinical testing; Clinical Evaluation; Clinical Testing; clinical test; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Development; developmental; cost; blood infection; bloodstream infection; Sepsis; Outcome; manufacturing plants; production plants; manufacturing facility; pathogen; innovate; innovative; innovation; resistant; Resistance; anti-microbial; antimicrobial; iPS; iPSC; iPSCs; induced pluripotent cell; inducible pluripotent stem cell; induced pluripotent stem cell; commercial application; prototype; commercialization; biological systems; Phase I Study; phase 1 study; hemocompatibility; infection risk; rate of infection; infection rate
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00